PARP1 and breast cancer: BRCAness phenotype in breast cancer has been shown to be highly correlated with the response to platinum-based chemotherapy and PARP inhibitors in BRCA1 and BRCA2 germline wild-type triple negative breast cancer (TNBC) [9, 10].